Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Shares Outstanding (Weighted Average) (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Shares Outstanding (Weighted Average) readings, the most recent being $93.2 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 17.18% to $93.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.2 million through Dec 2025, up 17.18% year-over-year, with the annual reading at $93.2 million for FY2025, 17.18% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $93.2 million in Q4 2025 for Terns Pharmaceuticals, up from $91.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $93.2 million in Q4 2025 and bottomed at $15.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $57.8 million, with a median of $71.3 million recorded in 2023.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 9198.25% in 2021 before it increased 4.3% in 2024.
  • Terns Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $22.7 million in 2021, then surged by 58.69% to $36.0 million in 2022, then surged by 97.76% to $71.3 million in 2023, then increased by 11.57% to $79.5 million in 2024, then grew by 17.18% to $93.2 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Shares Outstanding (Weighted Average) are $93.2 million (Q4 2025), $91.6 million (Q3 2025), and $91.6 million (Q2 2025).